

Nosha Farhadfar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3713686/publications.pdf>

Version: 2024-02-01

31
papers

753
citations

623188

14
h-index

552369

26
g-index

35
all docs

35
docs citations

35
times ranked

1133
citing authors

#	ARTICLE	IF	CITATIONS
1	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	1.7	10
2	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	2.5	5
3	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
4	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 335.e1-335.e17.	0.6	5
5	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	3.4	32
6	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	0.6	3
7	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1150-1163.	1.3	2
8	Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. <i>Cancer Medicine</i> , 2021, 10, 70-78.	1.3	26
9	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	2.0	15
10	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	2.0	12
11	Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 183.e1-183.e7.	0.6	6
12	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 264.e1-264.e7.	0.6	13
13	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6
14	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 410-422.	0.6	13
15	National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	0.8	90
16	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	0.6	72
17	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 679.e1-679.e8.	0.6	10
18	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma—type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	2.5	24
20	Microbiota phylogenic analysis revealed decreased abundance of <i>Faecalibacterium prausnitzii</i> , an anti-inflammatory commensal bacterium, in patients with chronic graft-versus-host disease. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 263-265.	0.6	3
21	Severity of Acute Graft-versus-Host Disease and Associated Healthcare Resource Utilization, Cost, and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1007.e1-1007.e8.	0.6	5
22	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury—Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2020, 3, e1918668.	2.8	40
23	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	2.0	47
24	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
25	Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2001-2010.	2.0	8
26	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011.	3.4	39
27	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27
28	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	2.5	34
29	Outcomes of rituximab—BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	2.0	17
30	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
31	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89